Forecast Of The Day: Colgate-Palmolive’s Oral, Home, and Personal Care Revenues
What?
Colgate-Palmolive’s (NYSE:CL) Oral, Home, and Personal Care Revenues rose from $13.2 billion in 2019 to about $13.7 billion in 2020. Trefis expects the metric to rise to about $14.5 billion in 2021 and to around $14.9 billion in 2022.
Why?
Relevant Articles
- Should You Pick Colgate-Palmolive Stock Over Monster Beverage After The Latter’s 2x Gains This Year?
- Should You Pick Colgate-Palmolive Stock After A Q3 Beat And 4% Gains This Month?
- Is Colgate-Palmolive Stock A Better Pick Over Marriott?
- Which Is A Better Consumer Defensive Pick – Kimberly-Clark Or CL Stock?
- Should You Buy Colgate-Palmolive Stock At $80?
- Should You Buy This Households & Personal Products Company Over Colgate-Palmolive Stock?
While growth picked recently due to the Covid-19 pandemic and the stay-at-home trend, we expect longer-term growth to be driven by innovation-led new product launches and higher pricing.
So What?
We don’t think the projected growth is priced into CL stock yet. We value CL at about $86 per share, about 13% ahead of the current market price.
See Our Complete Analysis For Colgate-Palmolive
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates